For nearly two decades, Flovent HFA helped millions of children manage asthma safely and reliably. Families and doctors trusted it because it worked, was widely covered by insurance, and was easy for children to use.

But in 2024, GlaxoSmithKline (GSK) discontinued Flovent HFA after years of price increases.

A Senate investigation led by U.S. Senator Maggie Hassan later found the company avoided hundreds of millions of dollars in Medicaid penalties by pulling the drug from the market and replacing it with a new version that many families say is more expensive, harder to access, and more difficult for children to use.

Parents and clinicians report that the sudden change created serious problems for families managing asthma. Some children experienced worsening symptoms, higher costs, and barriers to getting medication that had previously kept them healthy.

No child should struggle to breathe because a pharmaceutical company prioritized profits over patient access.

We call on GlaxoSmithKline leadership and U.S. health regulators, including the U.S. Department of Health and Human Services and the FDA, to restore affordable access to effective asthma inhalers and ensure companies cannot exploit loopholes that put children’s health at risk.

We call to hold GSK accountable! 

Sign this petition to demand accountability from GSK and protect access to life-saving asthma medications.